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Abstract
Numerous concerns have emerged regarding the dangers of extended benzodiazepine use and
abuse, as well as continued prescribing by medical professionals despite related
contraindications. Primary care physicians (PCPs) may find decisions around benzodiazepine
prescription and related patient encounters to be especially challenging. Little is known on the
efficacy of routine medical training and supervision/consultation models in preparing emerging
PCPs for managing the dilemmas that may ensue with regards to prescribing benzodiazepines.
The present study sought to begin addressing this gap by conducting an initial qualitative inquiry
into the training and supervision experiences and needs of a group of current family medicine
residents. A 30-minute semi-structured focus group interview (consisting of four participants)
was conducted via video. Two main themes, Variability in Resources and Supports and
Patient–Provider Interactions, were identified through thematic analysis. Participants highlighted
concerns that inconsistencies in resources and supervisory approaches to benzodiazepines might
adversely impact their therapeutic relationship with patients, and an initial hypothesis regarding
this possible association was presented for further research. Participants identified increased
empathy from supervisors around this concern as a primary area of need for future support.
Limitations of the study, implications for practice, and future directions for research were
discussed. The present study found that a better understanding of the early training and
supervision experiences of emerging primary care providers around benzodiazepines will be
critical in supporting the next generation of providers, improving patient care, and shaping future
prescribing practices related to this difficult class of medications.
This dissertation is available in open access at AURA, http://aura.antioch.edu/
and Ohio Link ETD Center, https://etd.ohiolink.edu/.
Keywords: benzodiazepines, prescription, primary care, dilemmas, training, supervision
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Physician Training and Support in Managing Dilemmas Around Benzodiazepine Prescribing
On September 23, 2020, the U.S. Food and Drug Administration (FDA) announced that it
would require an update to the Boxed Warning label on benzodiazepine prescriptions to include
the risks of misuse, abuse, physical dependence, addiction, and withdrawal (U.S. Food and Drug
Administration, 2020). This reflected a number of growing concerns regarding this widely used
class of psychotropic medication. In 2019, an estimated 92 million benzodiazepine prescriptions
were dispensed from U.S. outpatient pharmacies (U.S. Food and Drug Administration, 2020).
Around 5% of U.S. adults ages 18 through 80 (over 10 million individuals) were estimated to
receive one or more benzodiazepine prescriptions in 2008 (Olfson, King, & Schoenbaum, 2015).
A 2019 cross-sectional study, conducted using data from the National Survey on Drug Use and
Health Data, revealed that recent numbers may be significantly higher than previous estimates,
with over 30.6 million U.S. adults reporting (prescription and non-prescription) use of one or
more benzodiazepines between 2015 and 2016 (Maust, Lin, & Blow, 2019). Additional
longitudinal data collected between 2003 and 2015 support a steady increase in the number of
benzodiazepine prescriptions issued in outpatient settings over the past decade, particularly by
non-psychiatric providers (Agarwal & Landon, 2019).
Growing Concerns Around Benzodiazepines
Benzodiazepines are one of the most frequently misused and abused types of prescription
medications. Maust et al. (2019) found that nearly 20% of reported cases of benzodiazepine use
between 2015 and 2016 could be classified as misuse (e.g., using without a prescription, taking
different doses than prescribed). These medications have a high potential for dependence and
addiction due to their ability to produce almost immediate sedative and euphoric effects (Brett &
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Murnion, 2015; Siriwardena, 2017). In 2011, over 500,000 (one half million) emergency
department (ED) visits occurred in relation to benzodiazepine use (Substance Abuse and Mental
Health Services Administration, 2013). Seventy-nine percent of these visits were related to
non-medical use, and 24.2% of these visits involved co-occurring alcohol consumption (Olfson
et al., 2015). These ED admission statistics represented an approximate 154% increase from
2004 numbers, illustrating a growing problem of benzodiazepine-related physical and mental
health emergencies (Substance Abuse and Mental Health Services Administration, 2013).
A number of dangers have been linked to prolonged and/or excessive benzodiazepine
use, including a) drowsiness, confusion, and motor impairments (Authier et al., 2009; Brett &
Murnion, 2015; Landry, Smith, McDuff, & Baughman, 1992); (b) potentially enduring deficits in
a number of cognitive abilities (Crowe & Stranks, 2017); and (c) an increase in psychiatric
symptoms related to depression and anxiety (Brunette, Noordsy, Xie, & Drake, 2003; Jones,
Nielsen, Bruno, Frei, & Lubman, 2011). Benzodiazepines are one of the most commonly
encountered drugs in overdose-related deaths, frequently found in combination with opioids and
alcohol (Olfson et al., 2015). A growing body of research supports that chronic benzodiazepine
use may be especially dangerous in the elderly population, with psychomotor impairments
resulting in an increased likelihood of falls (Pariente et al., 2008) and possible memory
impairments. A possible link between benzodiazepine use in the elderly and dementia is
currently under investigation (Billioti de Gage et al., 2012; Markota, Rummans, Bostwick, &
Lapid, 2016; Opondo et al., 2012).
In addition to the number of potentially adverse side effects associated with long-term
benzodiazepine use, the process of withdrawal (particularly when use is abruptly stopped) can
induce many unpleasant and potentially life-threatening physical and psychological symptoms
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including catatonia, seizures, extreme anxiety (Fixsen & Ridge, 2017), dysphoria (Baandrup,
Fagerlund, & Glenthoj, 2017), and even psychotic experiences (Brett & Murnion, 2015; Morales
et al., 2017). These symptoms can severely limit an individual’s ability to function in a number
of everyday situations (Fixsen & Ridge, 2017) and may also increase the likelihood of
developing and/or acting on suicidal thoughts (Dodds, 2017), engaging in other impulsive or
self-endangering behaviors (Authier et al., 2009), or directing aggression toward others (Jones et
al., 2011).
Inappropriate Benzodiazepine Prescription Practices Persist
Given their relatively high potential for misuse, abuse, and psychological and physical
dependence, and their host of dangerous side effects and withdrawal symptoms, benzodiazepines
require close medical monitoring. The majority of benzodiazepine prescriptions appear to be
managed by non-psychiatric practitioners (Olfson et al., 2015). Within recent years, many
psychotropic medications, including benzodiazepines, have been increasingly prescribed and
followed by primary care physicians (PCPs; Hedenrud, Svensson, & Wallerstedt, 2013).
Concerns have arisen with regards to the abilities of PCPs to manage these medications,
particularly in psychiatrically complex patients who may require a number of psychotropic
medications (Ballester, Filippon, Braga, & Andreoli, 2005). Additionally, despite recent
adjustments in recommended best practices around the use of benzodiazepines in the treatment
of anxiety (Baldwin et al., 2005) and insomnia (Morgenthaler et al., 2007; Schutte-Rodin, Broch,
Buysse, Dorsey, & Sateia, 2008), and cautions against their use in elderly patients, a
considerable number of new prescriptions appear to be inappropriately issued on a regular basis
(Cloos & Ferreira, 2009; Opondo et al., 2012; Siriwardena, 2017).
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Providers Face Dilemmas Around Prescribing Benzodiazepines
Research suggests that medical providers face a number of ethical, personal, and
interpersonal dilemmas when asked by a patient to begin a new benzodiazepine prescription or to
continue benzodiazepine treatment initiated by another professional (Anthierens, Habraken,
Petrovic, & Christiaens, 2007; Bradley, 1992a; Siriwardena, Qureshi, Gibson, Collier, &
Latham, 2006). Face-to-face encounters around these medication requests may be rife with a
number of difficult interactions on both patient (Fixsen & Ridge, 2017) and provider (Anthierens
et al., 2007; Bendtsen, Hensing, McKenzie, & Stridsman, 1999; Bradley, 1992a) ends. Literature
around both broad medication issues (Upshur, Bacigalupe, & Luckmann, 2010) as well as
benzodiazepine medications in particular (Iliffe et al., 2004; Mah & Upshur, 2002) suggest that
significant gaps frequently exist between patient and provider understanding, preferences,
intentions, and concerns within these encounters.
In recent years there has been an increasing emphasis on building interpersonal and social
communication competencies in medical trainees (Batalden, Leach, Swing, Dreyfus, & Dreyfus,
2002). However, training programs appear to be highly variable with regards to how they
implement curricula around these competencies (Cape, Hannah, & Sellman, 2006; Kelleher,
2007). There does not appear to be any recent research on the firsthand experiences of medical
practitioners regarding the effectiveness of their training in preparing them to manage
challenging encounters around controlled psychotropic substances (such as benzodiazepines) in
actual practice. The present study sought to begin filling this gap by investigating the subjective
experiences of a group of emerging medical professionals (family medicine residents) with
regards to training, supervision, and consultation around benzodiazepines.
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Literature Review
The Rise of Benzodiazepines
Benzodiazepines are a group of sedative hypnotic medications typically prescribed for
the treatment of acute anxiety and panic symptoms, as well as insomnia. In addition to offering
anxiolytic benefits, benzodiazepines may also be used in medicine for their anticonvulsant,
muscle relaxant, and anesthetic effects (Julien, 2013). Commonly prescribed benzodiazepines
include short-acting agents, such as alprazolam (Xanax), triazolam (Halcion), and midazolam
(Versed); intermediate-acting agents, such as lorazepam (Ativan) and clonazepam (Klonopin);
and longer-acting agents, such as diazepam (Valium). Benzodiazepines first emerged in the
1960s as an alternative to the prevailing barbiturate drugs of the time, such as amobarbital
(Wick, 2013). Due to their relative safety in comparison to these former drugs, benzodiazepines
subsequently experienced a surge in popularity. In 2013, alprazolam was the number one most
prescribed psychotropic medication in the United States; this represented a stable trend from
previous years (Grohol, 2018). Another benzodiazepine, lorazepam, was similarly high on the
list, ranking as the fifth most frequently prescribed psychotropic in 2013, with over 28 million
prescriptions issued (Grohol, 2018). Per CDC estimates, benzodiazepines were prescribed at an
overall national average of 37.6 prescriptions per 100 individuals in 2012 (Paulozzi, Mack, &
Hockenberry, 2014). Frequency of benzodiazepine prescription appears to be highly variable
across states, with Southern states such as Alabama, Tennessee, and West Virginia exhibiting
higher prescribing rates than others (Paulozzi et al., 2014). Maust, Lin, Blow, and Marcus (2018)
analyzed state and county-wide benzodiazepine prescription data across the U.S. from the 2015
Medicare Public Use Files (PUF). Counties with lower median income levels, lower levels of
educational attainment, and higher rates of opioid prescriptions were associated with higher
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numbers of benzodiazepine prescriptions, even after adjustments were made regarding
availability of mental health resources (Maust et al., 2018).
Long-term benzodiazepine use appears to be more frequent in females than in males,
though a considerable proportion of illicit use may be attributed to males (Olfson et al., 2015).
Individuals with existing mental health and substance use histories may be more likely to
develop dependence and/or engage in benzodiazepine misuse (Baandrup et al., 2017; Brunette et
al., 2003). Additionally, socioeconomic factors have been implicated in long-term
benzodiazepine use (Morales-Suarez-Varela, Jaen-Martinez, Llopis-Gonzalez, & Sobrecases,
1997), with users citing a desire to escape from overwhelming life stressors (Fixsen & Ridge,
2017).
Risks Associated with Prolonged Use
Benzodiazepines act by enhancing the binding capacity of gamma-aminobutyric acid
(GABA), a key neurotransmitter involved in inhibitory responses of the central nervous system,
to its cellular receptor (Campo‐Soria, Chang, & Weiss, 2006; Julien, 2013). This can promote
perceptions of physical relaxation and a sense of subjective wellbeing.
Despite their assumed safety in comparison to previous sedative hypnotic medications,
and their seemingly therapeutic short-term effects, a growing body of research suggests that
benzodiazepines may pose a number of unexpected risks with long-term use. High doses of
benzodiazepines may cause paradoxical agitation in the forms of elevated anxiety, irritability,
hostility, and aggression (Julien, 2013). Crowe and Stranks (2017) conducted a meta-analysis on
the relationship between extended benzodiazepine use and various cognitive abilities and found
statistically significant adverse effects on working memory, visuospatial construction, divided
attention, and more general sustained attention in benzodiazepine users. Some of these cognitive
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challenges appeared to persist even after withdrawal and sustained abstinence (Crowe & Stranks,
2017). These deficits may adversely impact learning and related school and work performance in
children and adults (Julien, 2013).
Results from two large cohort studies in France and the United Kingdom found all-cause
mortality to be significantly higher in benzodiazepine users (as well as those who used both
benzodiazepines and antidepressants) than those who used neither medication across a 12-month
time period (Palmaro, Dupouy, & Lapeyre-Mestre, 2015). Additional studies have observed a
potential association between benzodiazepine use and risk of premature mortality, though more
research is warranted regarding causality (Charlson, Degenhardt, McLaren, Hall, & Lynskey,
2009). Many mediating variables may play a role in mortality and overall health, including
number of adverse childhood experiences (ACEs), which appears to be associated with a higher
likelihood of being prescribed one or more psychotropic medications (Anda et al., 2007). It is
therefore possible that patients with other risk factors for premature mortality may be more likely
to be prescribed benzodiazepines and other medications. Research has also demonstrated that
individuals who use benzodiazepines may be at an increased risk for suicidal ideation and
attempts, particularly during withdrawal (Dodds, 2017; Jones et al., 2011).
Long-term use of benzodiazepines is prevalent (Neutel, 2005). Physical and
psychological dependence may develop within less than one month of regular benzodiazepine
use, even at established therapeutic doses (Authier et al., 2009; Julien, 2013). Unpleasant
withdrawal symptoms may develop after only two weeks of regular use (Brett & Murnion,
2015). Individuals may endorse fear of withdrawal effects as a primary motivation for continued
benzodiazepine use, even when the medications are only minimally helpful (Barter & Cormack,
1996). Physical symptoms of withdrawal may include tachycardia, hypertension, tremors, chest
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pain, convulsions (Brett & Murnion, 2015; Schweizer & Rickels, 1998; Tyrer, Murphy, & Riley,
1990) and potentially life-threatening catatonia (Deuschle & Lederbogen, 2001). Psychological
symptoms may include: (a) feelings of dread, overwhelming panic, exaggerated anxiety,
paranoia (Aguiluz, Alvarez, Pimentel, Abarca, & Moore, 2018; Fixsen & Ridge, 2017);
(b) intrusive thoughts (Baandrup, Fagerlund, & Glenthoj, 2017); (c) extreme sensitivity to
various sensory stimuli (Authier et al., 2009); (d) depression (Baandrup et al., 2017);
(e) insomnia (Tyrer, Murphy, & Riley, 1990); (f) nightmares, personality changes, irritability
(Aguiluz et al., 2018; Schweizer & Rickels, 1998); (g) aggression (Jones et al., 2011); and
(h) perceptual disturbances (Brett & Murnion, 2015; Martin-Kleisch & Zulfiqar, 2017). In severe
cases, individuals may meet the full diagnostic criteria for mania and/or psychosis (Morales et
al., 2017). Firsthand accounts from individuals struggling with withdrawal have also described
extreme feelings of depersonalization, derealization, and feelings of alienation and isolation from
the world (Brett & Murnion, 2015; Fixsen & Ridge, 2017). Medical decisions regarding whether
to continue benzodiazepine prescriptions, even when discontinuation may be clinically
appropriate, are complicated by the many potential dangers of withdrawal syndrome. Physicians
are advised to discontinue benzodiazepine medications with caution, through a gradual tapering
process (Aguiluz et al., 2018; Landry et al., 1992).
Changing Recommendations for Prescribing Benzodiazepines
Due to established concerns about various adverse health effects and the dangers of
withdrawal, numerous guidelines have been issued advocating that benzodiazepine prescription
be limited to a maximum of two to four weeks and to only the most severe circumstances
(Benzodiazepine Committee, 2002; Janhsen, Roser, & Hoffmann, 2015; Salzman, 1991).
Additionally, while benzodiazepines were formerly indicated in the treatment of anxiety and
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insomnia, pharmacological recommendations around these conditions have shifted following
extensive research on alternative best practices. For anxiety disorders, which are frequently
chronic conditions, selective serotonin reuptake inhibitors (SSRIs) are now the recommended
frontline psychotropic intervention (Baldwin et al., 2005). Though the therapeutic effects of
SSRI medications tend to have a longer latency period (taking anywhere from two weeks to two
months to take full effect) than benzodiazepines (which offer individuals immediate relief), they
are believed to be a more efficacious treatment in the long term, and discontinuation of SSRIs
appears to be associated with fewer adverse side effects (Offidani, Guidi, Tomba, & Fava, 2013).
Additionally, psychotherapeutic or behavioral interventions (particularly in the form of cognitive
behavioral therapy [CBT]) have been demonstrated to be as effective as pharmacological
treatments for anxiety, and, in combination with medication, may offer an individual the most
lasting reduction in symptoms (Roy-Byrne et al., 2010). For the treatment of insomnia,
behavioral interventions are increasingly advocated as a first line of intervention before
beginning treatment with medication (Morgenthaler et al., 2007; Schutte-Rodin et al., 2008).
Alternative sleep medications known as “Z-drugs” (such as zolpidem) are being increasingly
explored (Lieberman, 2007), though, similar to benzodiazepines, concerns have emerged
regarding their tolerability and safety in cases of long-term use (Siriwardena et al., 2006).
Increasing Benzodiazepine Management in Primary Care
Despite established changes in best practices, new benzodiazepine prescriptions continue
to be issued at an increasing rate (Anderson, Stowasser, Freeman, & Scott, 2014; Cloos &
Ferreira, 2009; Siriwardena, 2017). Additionally, a number of prescriptions continue to be issued
for elderly patients, despite the growing literature on this age group’s particular vulnerability to
adverse benzodiazepine-associated effects (Olfson et al., 2015; Opondo et al., 2012). Gerlach,
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Maust, Leong, Mavandadi, and Oslin (2018) investigated the transition to long-term
benzodiazepine use in a sample of 576 older adult patients who had been issued new
prescriptions by non-psychiatric prescribers between 2008 and 2016; results showed that over
26% of these patients met criteria for long-term use. Medication decisions around extended
prescriptions were not predicted by higher anxiety or depression levels as the researchers had
anticipated (Gerlach et al., 2018).
In recent years, due to relative shortages of psychiatric professionals, benzodiazepine
prescriptions have become increasingly managed by non-psychiatric providers, such as primary
care providers (PCPs). This setting has been associated with some of the more problematic
prescribing practices (Mugunthan, McGuire, & Glasziou, 2011; Rutkow, Turner, Lucas, Hwang,
& Alexander, 2015; Siriwardena et al., 2010). PCPs are increasingly confronted with patient
requests for new or continued benzodiazepine prescriptions. In some cases, they may be asked by
patients to begin a new medication for experiences of overwhelming anxiety, panic, and/or
insomnia (Johnson & Longo, 1998; Linden, Bär, & Geiselmann, 1998). Some patients may
endorse previous benzodiazepine use (as prescribed or illicitly) and observed benefits.
Additionally, patients may have been prescribed a benzodiazepine medication (either short term
or long term) by another provider (in Primary Care, following an ED admission, following a stay
in an inpatient psychiatric setting, etc.) and may require a refill. Though patients may have been
issued an initial benzodiazepine prescription by one medical professional, they may not be
followed by that provider long term. Therefore, the PCP is often the de facto provider expected
to make further decisions regarding continuation or discontinuation of this prescription (Zandstra
et al., 2004). This can place PCPs in a difficult position where they must weigh the costs and
benefits of various treatment options and negotiate them with the patient.
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Provider Dilemmas Around Prescribing Benzodiazepines
PCPs may endorse particular ambivalence and discomfort in making decisions around
prescribing benzodiazepines, characterizing these experiences as dilemmas (Bradley, 1992a;
Marienfeld, Tek, Diaz, Schottenfeld, & Chawarski, 2012; Wain, Khong, & Sim, 2007). The
well-known dangers of both extended benzodiazepine use and discontinuation are apt to
make decision-making around medication maintenance or adjustment particularly
challenging for physicians. Bendtsen et al. (1999) conducted a phenomenological critical
incident study on the quality of dilemmas encountered by 213 Swedish general practitioners
(GPs) regarding patient requests for benzodiazepine prescriptions and found a number of salient
themes. Dilemmas around concern for the wellbeing of patients, integrity of the physician being
compromised during decision-making, limited time for individual visits, and difficulties trusting
the patient to appropriately handle medications were reported. Major consequences of dilemmas
included damage to the patient–provider relationship or prescribing benzodiazepines in haste due
to time limitations. The authors made recommendations for increased training in communication
and negotiation skills, as well as more time with individual patients (Bendtsen et al., 1999).
These findings built upon the earlier work of Bradley (1992b) in English GPs, which explored
more general themes related to provider discomfort around medications (psychotropic and nonpsychotropic). Some of the most frequent themes included (a) concerns around drug toxicity,
(b) failure to live up to own expectations, (c) concerns about the appropriateness of treatment,
(d) ignorance/uncertainty about management, and (e) concerns about negative patient evaluation
(Bradley, 1992b).
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Numerous Variables Influence Prescribing Practices of Providers
A number of variables have been shown to influence the more general prescribing
decisions of providers. Patient demographic variables such as (a) age (Bradley, 1992a; Hedenrud
et al., 2013), (b) gender (Bradley, 1992b), (c) race and ethnicity (Burgess, Van Ryn,
Crowley-Matoka, & Malat, 2006), (d) socioeconomic status (Bradley, 1992a), and (e) education
level (Cook, Marshall, Masci, & Coyne, 2007) may play a role. Perceptions or assumptions
regarding patient needs, abilities to function, and severity of social stressors may play a role in
decision-making around prescribing psychotropic medications (Hedenrud et al., 2013; Rogers et
al., 2007; Šubelj, Vidmar, & Švab, 2010). Evidence for previous or ongoing substance use or
abuse serves as a common deterrent for prescribing benzodiazepines (Bendtsen et al., 1999;
Marienfeld et al., 2012). Friends and family members may affect patient motivations and beliefs
around benzodiazepines, as well as provider concerns about potential risks and benefits of
prescribing (Hedenrud et al., 2013). Patient expectations of a medication (Hedenrud et al., 2013)
and seeming responsibility (Dybwad, Kjølsrød, Eskerud, & Laerum, 1997) may also affect
providers’ prescribing decisions.
A number of provider variables have also been shown to play a role in guiding decisions
around benzodiazepine prescription, including provider knowledge and comfort regarding
psychotropic medications and mental health (Hedenrud et al., 2013; Sirdifield et al., 2013) and
ability to manage uncertainty or complexity (Cook et al, 2007; Siriwardena et al., 2010).
Additionally, provider feelings of self-efficacy, confidence, assertiveness, and comfort with
negotiating (Anderson et al., 2014; Hedenrud et al., 2013) may impact his perceived ability to
comply with or challenge patient requests. Specific to self-efficacy, additional variables related
to provider skills, attitudes, influence, and overall support within an organization may be
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relevant; providers who are lacking in knowledge and practice may still feel confident and
effective within their role through the buffering influence of colleagues or other supports
(Anderson et al., 2014). PCPs may experience concerns about boundaries between primary care
and other prescribing contexts and may worry about how their behaviors will influence relations
with colleagues (Anderson et al., 2014; Hedenrud et al., 2013). Ethically, providers may feel a
sense of professional responsibility or obligation to make appropriate decisions regarding risk
management and harm reduction (Rogers et al., 2007). PCPs may experience fewer concerns
around addiction in older adults and may be more likely to associate continuation of
benzodiazepines with compassionate treatment and discontinuation of these medications with
harsh treatment (Cook et al., 2007). Personal use of benzodiazepines may also influence provider
decisions around patient prescriptions (Linden & Gothe, 1998; Srisurapanont, Garner, Critchley,
& Wongpakaran, 2005).
In addition to a number of individual patient and provider variables, several
patient–provider relationship variables appear to factor into encounters surrounding
benzodiazepine medication management. Familiarity with a patient and related trust (Dybwad et
al., 1997; Marienfeld et al., 2012; Wain et al., 2007), desire to maintain a good patient–provider
relationship (Wain et al., 2007), and fear of patient dissatisfaction and/or resistance (Bendtsen et
al., 1999; Cook et al., 2007) may persuade providers to comply with patient requests for
benzodiazepine prescriptions. Previous interpersonal experiences with other patients regarding
benzodiazepine requests may also influence provider decision-making (Parr, Kavanagh, Young,
& McCafferty, 2006). Psychiatrists identified feeling manipulated or deceived by a patient as a
common reason for refusing benzodiazepine prescriptions (Marienfeld et al., 2012). These
characteristics were associated with greater concern for potential misuse/abuse down the line or

15
diversion to other individuals within the household (Marienfeld et al., 2012). Additionally,
overall ease of communication (which encompasses both provider and patient abilities) may play
a substantial role in the outcomes of encounters regarding medication requests (Bradley, 1992b;
Cook et al., 2007; Hedenrud et al., 2013). Gaps in knowledge, understanding, preferences, and
communication between patients and providers are common and may create additional tensions
(Iliffe et al., 2004; Mah & Upshur, 2002; Parr et al., 2006).
Finally, variables related to broader workplace context and additional societal and
cultural concerns may emerge in benzodiazepine-related medical encounters. Workplace
constraints such as time, money, technology (Anderson et al., 2014; Hedenrud et al., 2013), and
workload (Šubelj et al., 2010) may affect providers’ comfort, willingness, and abilities to
prescribe a number of medications, including benzodiazepines. Media may impact patient
knowledge and perceptions of certain medications (Hedenrud et al., 2013). Additionally, broader
regional guidelines for prescribing practices, as well as pharmacological companies, may
influence provider responsibilities and related decision-making (Hedenrud et al., 2013).
Research Gaps and Purpose of Current Study
Given the high incidence of benzodiazepine-related medical and mental health
emergencies, growing research findings on the potential dangers that both extended use and
withdrawal may pose, and continually high rates of inappropriate prescribing practices, there is a
clear need for continued support of both patients and providers around these issues. The bulk of
existing literature on provider difficulties around prescribing benzodiazepines appears to focus
on the experiences of established medical providers. However, broader research suggests that
emerging medical professionals (medical residents) frequently lack confidence in their clinical
abilities to manage patient requests for possible drugs of dependence and may be particularly
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vulnerable to stress and distress with regards to these issues (Ballester et al., 2005; Hedenrud et
al., 2013; Taverner, Dodding, & White, 2000). With controlled substances, such as
benzodiazepines, which have a high potential for misuse, abuse, and physical and psychological
dependence and addiction, provider knowledge, confidence, and competency regarding these
issues is critical. A longitudinal study conducted on medical students across four different
training programs in New Zealand illustrated an increase in competence (knowledge and skills)
as training progressed, but a notable decrease in students’ subjective perceptions of adequacy and
self-efficacy in managing issues related to substance abuse, with fewer medical students
expressing an interest in working with patients with addiction as training progressed (Cape et al.,
2006). The authors speculated that this may be related to increased awareness of the complexity
of treating substance use disorders, or due to having more negative experiences and perceptions
of substance users as “patients to be avoided” over time (Cape et al., 2006). General research on
physician knowledge and attitudes around substance use and interacting with potential substance
users suggests highly variable training on these issues, even in more experienced professionals
(Kelleher, 2007). Education on mental health issues (Ballester et al., 2005) as well as
interpersonal communication skills, also appears to be highly variable across training programs,
despite recent attempts to expand these competencies (Berkhof, van Rijssen, Schellart, Anema,
& van der Beek, 2011). Training interventions for improving psychotropic prescription practices
in primary care have shown mixed results, with many of them demonstrating short-term
improvements in provider knowledge, but minimal long-term gains with regards to provider
confidence (Figueiras, Sastre, & Gestal‐Otero, 2001; Midmer, Kahan, & Marlow, 2006).
Efforts are continually underway to develop and improve training in psychotropic
medication management in primary care, particularly as guidelines for best prescribing practices
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continue to shift, and more psychotropic medications are being managed in this setting.
However, there are few studies to date detailing the firsthand experiences and subjective
accounts of emerging medical trainees on handling difficult patient encounters around
psychotropic/controlled substance issues, such as those encountered with benzodiazepines. This
information will be particularly valuable in understanding how to continue improving training
and practice models to best inform and support upcoming generations of medical providers who
will likely face many new challenges and demands regarding benzodiazepines. The present study
sought to begin filling this gap by answering the following research question:
What are the experiences of medical residents with regards to training, supervision, and
consultation around managing benzodiazepine prescribing dilemmas?
The primary goal of this research was to identify, through direct accounts from residents,
preliminary areas where they may require additional training and support.
Method
Participants
Family medicine residents at a medical training program in New England were recruited
via email to participate in a 30-minute focus group interview (held virtually via Zoom video
conferencing). Permission was given by the medical institution to contact residents and conduct
the interview during a portion of regularly scheduled didactic trainings in order to minimize
additional time demands on residents. Efforts were made to emphasize the voluntary nature of
participation, and to ensure that training directors (who are in a position of authority/power
relative to residents) were not aware of who chose to participate, in order to minimize possible
coercion.
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In order to be included in the study, participants were required to have provided direct
care (face-to-face or telehealth) to patients for at least three months, and to have had at least one
experience in which they were asked to begin, discontinue, or adjust a benzodiazepine
prescription for a patient. Of the 16 residents contacted, four chose to participate in the focus
group. Due to the small sample size and the potential for participants to be easily identified by
training directors (who, as previously discussed, hold relative power over trainees) detailed
demographic information was not reported for this study. However, variability was observed in
certain sociodemographic areas (e.g., gender identity, race/ethnicity, prior medical training
programs). Participants were similar in terms of age and ranged from first-to second-year
residents. The medical residency program served a number of children and adults across the
lifespan in traditionally underserved suburban and rural communities. Integrated behavioral
health services had been established within this program for a number of years, though they were
in the earlier stages of implementation at certain training sites. The patient population served by
the participants in this study consisted of predominantly low-income adults of varying racial and
ethnic backgrounds. High rates of co-occurring mental health and substance use disorders as well
as co-occurring chronic illnesses (i.e., medically complex cases) were noted.
Design
This qualitative study was guided by a phenomenological approach to research
(Moustakas, 1994), as it sought to understand the lived experiences of medical residents with
regards to managing patient encounters related to benzodiazepines. This theoretical approach
emphasizes the gathering of in-depth firsthand accounts as a means of better understanding
human experiences (Van Manen, 2016). Phenomenological research methods are flexible and
include participant interviews, narratives, and/or ethnographies (Creswell, 2013).
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A focus group interview format was selected for data collection due to the efficiency it
offered with regards to scheduling and engaging multiple participants (Krueger & Casey, 2014).
In recent decades, focus groups have become a popular tool for collecting data on consumer
opinions and preferences in the field of marketing research (Morgan, 1998). However, their use
in social science research dates back to the early 1940s, when Paul Lazarsfeld and Robert Merton
developed this method as a means of identifying “salient dimensions of complex social stimuli as
a precursor to further quantitative tests” (Onwuegbuzie, Dickinson, Leech, & Zoran, 2009, p. 2).
Focus groups may appear less intimidating to many participants than individual interviews
(Krueger & Casey, 2014), and the social component is believed to increase feelings of
connectedness (Peters, 1993) and encourage more sharing from each participant (Vaughn,
Schumm, & Sinagub, 1996), producing a somewhat synergistic effect (Dilshad & Latif, 2013).
Rich data may also emerge from the patterns of social interactions that ensue within the group
(Onwuegbuzie et al., 2009) and participants may be more apt to offer suggestions for
improvements in programs and services via group format (Duggleby, 2005). The optimal number
of participants in a focus group varies. Krueger and Casey assert that five to eight participants is
ideal for non-marketing research topics, and caution against more than 10 individuals, as this
tends to limit each person’s contributions to the discussion. However, the authors also discuss the
increasing popularity of mini focus groups consisting of three to four participants, which increase
the probability of in-depth contributions from all members, though the overall range of
experiences represented in the group can be somewhat limited in a smaller sample (Krueger &
Casey, 2014).
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Measures
A semi-structured interview protocol that I developed was reviewed by medical training
directors for clarity and appropriateness of wording. Questions were primarily open-ended in
order to encourage participants to speak broadly of their experiences and engage in group
discussion, and I provided more specific probes as needed when moderating the focus group
discussion.
Interview Questions. The following open-ended interview questions and probes were
used with focus group participants:
1. Research suggests that decision making around benzodiazepines can be especially
difficult for primary care providers (PCPs), particularly when providers and patients
do not agree. Tell me about a time you were asked to begin, end, or adjust a
benzodiazepine prescription by a patient. You can focus on one memorable incident
or provide general details observed across multiple encounters if that’s easier.
a. What was your ultimate decision (e.g., prescribing, not prescribing, etc.)?
b. How comfortable/confident did you feel about your decision?
c. What made the decision difficult/easy?
d. Did you have any previous experience navigating these interactions?
e. What potential communication difficulties (if any) did you sense between you
and the patient?
2. Were you able to seek supervision/consultation as needed? If so, how
beneficial/influential was it in supporting you and your decision-making process?
3. In what ways do you feel your medical training prepared (or didn’t prepare) you to
navigate this interaction?
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4. What recommendations (if any) would you give to training programs in order to
better support the needs of trainees?
5. In what ways do you think behavioral health clinicians (BHCs) may be able to better
help with these dilemmas moving forward (if at all)?
Procedure
The steps of the process I used for conducting the focus group interview were as follows.
Participants were emailed a copy of the informed consent form, and it was reviewed in detail at
the beginning of the scheduled video meeting. Informed consent was obtained orally from all
participants before officially beginning the focus group interview. Participants were encouraged
to find a private location within their respective meeting spaces to ensure the confidentiality of
everyone in the group. In order to ensure maximum information security over video, a
HIPAA-compliant Zoom account was used to host the meeting. Though no protected health
information (PHI), as defined under the Health Insurance Portability and Accountability Act
(HIPAA), was shared during the focus group, this type of Zoom account offers higher overall
security and encryption standards. The interview was audio-recorded using a handheld digital
voice recorder. Raw data was transcribed directly from the device and reviewed for accuracy
immediately following the interview, and it was deleted from the device following my written
transcription. The written transcript was stored as a password protected document on a password
protected computer and was deleted following final data analysis. All possible individual
identifying information (e.g., names) were excluded from the written transcript. I had previously
engaged in a training experience at the medical institution from which the data was collected.
Though I had no previous relationship or interactions with any of the participants prior to the
study, efforts were made to mitigate possible bias by using a separate independent rater (another
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clinical psychological doctoral student) to analyze data. This rater was given access to the
written transcript of the focus group interview.
Results
Analysis
Interview data was analyzed in accordance with Braun and Clarke’s (2006) six-step
thematic analysis framework which provides an atheoretical multiphasic system for analyzing
qualitative data. Phases One through Three were performed independently by each of the two
raters and Phases Four through Six were performed as a group. During Phase One, raters became
familiar with the data set in its entirety. This was done through transcribing the original audio
recording (in the case of the primary researcher), as well as reading through the written interview
transcript multiple times until all content was clearly comprehended (by both raters). During
Phase Two, raters divided the content into discrete data extracts based on distinct ideas or topics
and began hypothesizing initial codes. A data extract is defined by Braun and Clarke (2006) as:
“an individual coded chunk of data, which has been identified within, and extracted from, a data
item” (p. 6). For the purposes of the current study, extracts were drawn from the written focus
group dialogue and consisted of individual sentences, phrases, or groups of sentences spoken by
a single participant that introduced new ideas or concepts. During Phase Three, raters began
searching the list of codes for possible themes. Singular or possibly irrelevant codes (e.g., codes
that were noted on only one occasion or clear asides that appeared unrelated to interview topics)
were set aside during this phase. During Phases Four through Six, raters met to review and
compare candidate themes, discuss and rework any possible discrepancies, and map out and
refine the final list of themes. A total of 87 data extracts were identified and reviewed for
themes. By the final stage of analysis, a total of two main themes and six sub-themes had been
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identified by raters. A visual representation of the final themes, sub-themes, codes, and number
of data extracts used for each is presented in Table 1. A sample data extract from each sub-theme
is presented in Table 2. Additionally, each theme is described in detail below.
Variability in Resources and Supports
Variability in Resources and Supports was identified as a main overarching theme. This
theme captured inconsistencies in quantity, quality, and types of resources and supports offered
to medical residents. Data extracts and codes encompassed training experiences in medical
school and residency, as well as general institutional and systemic variables (e.g., related to
insurance companies, the broader field of medicine). Some of these major content areas were
undoubtedly informed by the structure of the interview questions, which were targeted toward
training and supports. Sub-themes are discussed below.
Medical School. Participants all agreed that initiating new benzodiazepine prescriptions
had been strongly discouraged in their prior medical school training. Exposure to specific
coursework in substance use and controlled substances (including psychotropic medications)
appeared to vary across individual programs, though all focus group participants agreed that
more emphasis was placed on opioids than benzodiazepines in their training. Exposure to
benzodiazepines was noted to primarily occur during psychiatric rotations and in
optional/elective courses. When sharing about a specialized substance use course, one participant
emphasized: “Not every single medical student in my program took it. I think I was the only one
there, so it’s not like the medical curriculum put me there.” Participants also highlighted
differences in recommendations across professors with regards to prescribing benzodiazepines
and opioids. Participants expressed doubt that examples of “success stories” around controlled
substances shared in academic settings could be easily applied or translated into real-world
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clinical practice. One participant reported: “I remember thinking, oh that’s great, I’m glad you’ve
had success stories, but there was only one of those stories for every ten of my failures.”
Participants agreed that the general cautionary approach to initiating new prescriptions of both
benzodiazepines and opioids had been a valuable takeaway of their medical training. However,
they noted a general lack of coursework on “what to do if someone is already on them,” which
they identified as a repeated area of clinical difficulty throughout the interview.
Supervision/Consultation. Inconsistencies were also highlighted by the group in the
areas of supervision (by more experienced medical professionals) and consultation (with
professionals at similar levels of training). Participants reported frequent opportunities for
supervision and consultation around prescribing decisions and the ability to seek them out
whenever needed. However, they emphasized variability in the approaches of supervising
(attending) physicians with regards to managing benzodiazepines. Intentional efforts to ensure
that “all providers were on the same page” were identified as areas of need by participants,
though they also communicated concerns that forcing everyone to adhere to the same guidelines
could be viewed as “unethical.” The group discussed discrepancies between their relationships
with patients and those of attending physicians. One participant shared, with regards to
communicating decisions that may result in patients becoming angry: “It’s a lot easier for the
person supervising, because they don’t have to deal with it firsthand, and they don’t have any
kind of emotional attachment or desire to continue maintaining a relationship with the patient.”
The group identified a desire for increased “empathy” and understanding from supervisors with
regards to the way benzodiazepine-related decisions may impact the “patient–provider
relationship.”
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Institutional/Systemic Protocols. Lack of cohesiveness and uniformity were also
discussed with regards to larger institutional and systemic resources and protocols. This included
types of medications approved by insurance companies, logistical challenges related to tracking
prescriptions in the electronic health record (EHR) system, and broader “differences of opinion
on this class of medications” spanning the entire medical profession. One participant shared,
with regards to more general classes of controlled substances, “I feel like there are other
alternatives that exist, which are better for patients, but because of the financial burden around
them, hospitals, and I guess the healthcare system itself, discourage them.” Participants
acknowledged a general inability to change many of these variables, but concrete improvements
were suggested with regards to tracking and calculating medication doses. Participants reported
spending a considerable amount of time and effort performing calculations, checking calendars,
and cross-comparing records to ensure accuracy of patient reports and appropriate pill count
when responding to refill requests. Logistical fixes around sorting medications differently in the
EHR system and receiving automated notifications of when refills should be due were
recommended by the group.
Patient–Provider Interactions
Patient–Provider Interactions was also identified as a main theme. This theme captured
patient and provider emotions, provider decision-making processes, and other relationship
variables that were coded from the case examples provided by residents. Several sub-themes
emerged under the Patient–Provider Interactions theme. The ones determined to be most salient
through final analysis are discussed below.
Ambivalence. Consistent with previous research around prescribing dilemmas,
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ambivalence, tension, and inner conflict were apparent in the participants’ descriptions of
interactions with patients around benzodiazepines. Interactions were labeled as “challenges” on
more than one occasion. Emotions such as “dread” and “discomfort” were mentioned in multiple
examples. A decision was made to include codes related to these emotions under Ambivalence,
due to their seeming relation to uncertainty around best patient and provider practices. One
participant shared: “I dread these patients and I wish I didn’t, though sometimes maybe I
should.” Ambivalence was also coded in the context of balancing risks and benefits of prolonged
use versus withdrawal. One participant summarized: “Not only are they addictive, but if you stop
taking them acutely, you can actually die. With opiates [patients] can have very unpleasant
symptoms…But if you cut someone cold turkey off a benzodiazepine, you can kill them.”
Ambiguity or uncertainty in case examples with regards to “making the best decision,” and
phrases such as, “there is no good solution” were also included under this sub-theme.
Therapeutic Relationship. Another major content area discussed throughout the focus
group interview related to the “therapeutic relationship” between patient and provider.
“Negotiation” and “bargaining” were used to describe typical interactions with patients around
benzodiazepines. Additional variables related to “intent” and “motivation” of both patients and
providers were discussed throughout. Consistent with previous literature, concerns around being
“manipulated” by patients with regards to benzodiazepines (e.g., when being asked to refill
prescriptions early) were also shared by participants. This was discussed at both an individual
patient–provider level, and in the context of interactions between patients and multiple providers.
Participants discussed both real and hypothetical scenarios involving patients becoming aware of
inconsistencies between providers and “playing them off one another,” or “playing the system,”
in order to get their needs met. Language associated with behavior management, such as
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“reinforcement,” specifically concerns around “reinforcing that a pill will solve all their
problems,” were also discussed in the context of provider decisions around whether to comply
with patient requests for benzodiazepines.
Additionally, the therapeutic relationship was also emphasized in the context of treatment
priorities. Participants reported delaying decisions and discussions with patients around tapering
or switching medications for fear of “damaging” the patient–provider relationship. One
participant shared their thought process with more complex patients: “Maybe it would be better
to keep a good therapeutic relationship, so I can keep working on these other issues they have,
and maybe one day they’ll be more open to the other stuff.” Concerns around possible ruptures
or threats to the patient–provider relationship were also discussed extensively in the context of
supervision and other resources and supports. More specifically, participants appeared concerned
that inconsistencies in the approaches of attending physicians may “confuse” the patient or
prompt them to “question the judgment” of medical residents (as their primary providers).
Concerns were also shared by the group around being placed in a position of acting or appearing
“ingenuine” toward patients when relaying treatment decisions made by supervisors.
Empathy. Empathy was identified by the raters as an additional substantive content area
to be included under the Patient–Provider Interactions theme. Phrases such as, “I empathize
with,” “I understand why,” or “If I were in the patient’s shoes” were coded under this category.
Participants acknowledged an overall understanding of why benzodiazepines were helpful to and
desired by patients with regards to managing anxiety, particularly when other behavioral health
resources may not be accessible. One participant shared: “I understand why some of these
patients want the benzos. I don’t have anxiety. But from what some of these people describe, if I
were experiencing these things every day…trying to live my life and do my job, I would be like,
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‘Please give me these medications, because this is the only way that I’m going to survive.’” With
regards to potential “manipulation” by patients, one participant acknowledged: “Patients have
their ways, and it’s understandable. It’s human nature.”
Participants acknowledged the benefits of behavioral health services over
benzodiazepines while explaining how this is not always realistic for their patient population.
“Yes, it’s as effective, if not more effective, than actually taking the pill, because you’re actually
working through the problem rather than just pushing it down. But I think it’s difficult for them
time-wise.” Barriers related to time, transportation, and availability of appointments with mental
health providers were repeatedly described in the context of understanding patient motivations
and behaviors: “Sometimes it’s just more time efficient on the patient’s end to take a pill versus
going to a behavioral health appointment that will take them 45 minutes of traveling, an hour.
They’re busy, and it’s hard for them to take that much time out.” One participant noted: “There
aren’t that many behavioral health specialists in the area that we can reach out to when that
appointment need is there, who are actually available.” Comparisons were made with regards to
other medications in the context of wanting to “hear patients out.” “With most other medical
illnesses, if there’s a medicine that works, do we take it away from them? What if we say, ‘this
diabetes medication works great, but we’re taking it away from you now, because you should
actually be losing weight and eating healthier and exercising?’”
Discussion
The purpose of this qualitative study was to gain a preliminary sense of the experiences
of emerging primary care providers with regards to training, supervision, and consultation
around prescribing benzodiazepines (and navigating related patient encounters). A small sample
of current family medicine residents were recruited to participate in a semi-structured focus
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group interview. Two main themes, Variability in Resources and Supports and Patient–Provider
Interactions, were identified through thematic analysis.
Variability in Resources and Supports captured inconsistencies highlighted by
participants in the domains (sub-themes) of Medical School, Supervision/Consultation, and
Institutional/Systemic Protocols. With regards to Medical School, participants reported a
“hands-off” approach to prescribing benzodiazepines and a relative emphasis on opioids in
course content across all training programs. However, inconsistencies were noted in the
availability of and requirements for specific coursework in psychotropic medications and
controlled substances across programs, as well as the specific stances on benzodiazepines held
by professors within the same teaching institutions. Gaps and inconsistencies between theory and
practice were also discussed. Specific to Supervision/Consultation, participants noted that
supervision around benzodiazepines was always available, but that the approaches of supervising
(attending) physicians varied substantially with regards to benzodiazepines. With regards to
larger Institutional/Systemic Protocols, participants highlighted irregularities related to insurance
companies, technology for calculating and tracking medications, and differences in opinion on
benzodiazepines spanning the entire medical profession.
The second main theme, Patient–Provider Interactions, captured the range of thoughts,
feelings, motivations, decisions, and interpersonal exchanges between patients and providers
reported by participants. Three sub-themes (Ambivalence, Therapeutic Relationship, and
Empathy) were identified under this overarching category. Ambivalence (including tension,
dread, inner conflict, and difficulties balancing risks and benefits) was apparent in participants’
descriptions of patient interactions, which was consistent with previous research findings.
Descriptions of patient interactions in terms of “negotiation” and “manipulation” also resembled
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findings from previous qualitative studies on prescribing dilemmas around benzodiazepines.
However, a somewhat unexpected emphasis on the Therapeutic Relationship and Empathy were
identified in participants’ descriptions of patient interactions and concerns around
benzodiazepines.
A possible causal relationship between the two main thematic areas (Variability in
Resources and Supports and Patient–Provider Interactions) began to emerge from participants’
accounts and is mapped out in Figure 1 (using an arrow) as a preliminary hypothesis for further
research. Specifically, an overarching concern was highlighted by participants regarding the
ways inconsistencies in resources and supports (particularly in the area of supervision) may
manifest in patient–provider interactions. Parallels between the patient–provider and
resident–supervisor relationship were also apparent with regards to empathy. Participants
identified a desire for increased empathy from attending physicians toward their own empathy
and efforts to maintain a therapeutic relationship with patients as a primary need.
Implications for Practice
Though it was not surprising, in light of previous research findings, that participants
experienced ambivalence and discomfort in response to prescribing benzodiazepines, it was
somewhat unexpected that this discomfort was primarily attributed to concern for the
“therapeutic relationship” between patients and providers (as opposed to ethical, legal, substance
abuse, and other concerns mentioned in the previous literature). Concern for the therapeutic
relationship may be more generally pronounced in earlier stages of training and professional
development and may not be unique to benzodiazepine-related patient encounters. More research
is warranted in this area. However, findings of this study suggest that, at least with regards to the
difficult topic of benzodiazepines, emerging medical residents will likely benefit from increased
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empathy from supervisors and other supports around the ways inconsistent treatment decisions
may impact the patient–provider relationship. Participants also discussed the logistical
importance of developing uniform treatment approaches across supervisors and providers and
increasing the consistency of resources and protocols around managing benzodiazepines.
However, their accounts suggested that increased understanding and support from supervisors
may be the most salient (and easiest to address) need at their current level of training. An
appreciation of the particularly difficult crossroads medical residents occupy with regards to
benzodiazepines, due to their status as a trainee in a seemingly divided medical field, and their
concern for providing quality care to patients, will be useful in understanding how to best
support them during prescribing dilemmas. This may inform the types of supports offered by
both supervising/attending physicians and behavioral health consultants (BHCs) in integrated
primary care settings.
Limitations
The small sample size represented by the mini focus group (four participants total) is an
obvious limitation of the present study. Though the small size of the group appeared to
encourage more in-depth contributions from each participant, it is unclear whether the
experiences shared by participants would apply to other family medicine residents and emerging
primary care providers. A larger and more representative sample (spanning several different
medical schools and residency programs) would be necessary in order to determine whether the
themes found within this study could be generalized to the broader population of emerging
medical professionals. Though the focus group interview questions were primarily open-ended,
the overall research sought to understand training and supervision experiences. This inevitably
informed some of the codes and final themes determined to be most prevalent and relevant by
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myself and the additional rater, as a considerable amount of content fell within these areas.
Nevertheless, more content regarding the patient–provider relationship than anticipated was
identified in the data, and determined by raters to be a significant theme, regardless of specific
interview questions. Finally, though a focus group methodology may cultivate more depth within
a data set (through its discussion format), it may limit the overall range of experiences
represented across participants as it pulls for more consensus.
Future Research
Findings of this initial qualitative study highlighted a number of inconsistencies
encountered by a group of emerging primary care providers (family medicine residents) with
regards to medical school coursework, supervision/consultation, and broader systemic resources
and protocols for managing benzodiazepine prescriptions. Further research (with a much larger
and representative sample) is warranted in order to assess whether these inconsistencies are
present in other training settings. Restructuring of existing training models and programs in order
to increase the uniformity of coursework, supervision approaches, and general treatment
protocols may be warranted. Additional research into the developmental level of medical trainees
and related supervision needs and approaches may also be useful, as it is possible that the
accounts provided by residents in this study (all within their first two years of residency) were
not unique to the topic of benzodiazepines and represent a more general professional
development need. Further exploration and development of general models of supervision within
the field of medicine may be especially helpful. An emphasis on building frameworks for
conceptualizing the supervisor–supervisee relationship and possible parallel processes between
this relationship and the patient–provider relationship may be particularly apt. These concepts
have already been researched and discussed in other disciplines, such as psychology, and may be
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adapted as useful. Additionally, a larger scale inquiry into the systemic variables that continue to
divide the field of medicine with regards to benzodiazepines (in terms of pedagogy, practice, and
opinions) appears critical to understanding why so many seemingly inappropriate prescribing
practices persist, despite established changes in guidelines.
Conclusion
Though this preliminary qualitative study was inherently limited due to its small sample
size, a potentially salient hypothesis emerged with regards to the experiences of emerging
primary care professionals (family medicine residents) around managing benzodiazepines. Focus
group participants began to highlight a possible relationship between inconsistencies in
coursework, supervision, and larger systemic and institutional protocols, and the nature of
patient–provider interactions around benzodiazepines. Concerns that inconsistencies in these
areas (often beyond the control of medical residents) might adversely impact the therapeutic
relationship, as well as a desire for more empathy from supervisors regarding this concern were
highlighted. Further research is recommended in order to see if these concerns are shared by
other emerging professionals. General developmental levels are apt to play a role in how
providers experience and navigate difficult prescribing decisions and patient interactions (e.g.,
emerging professionals may experience more stress and ambivalence than experienced
professionals). However, better understanding the concerns of emerging professionals and
intervening at these earlier stages of training (e.g., medical school and residency) will be a
critical first step in increasing confidence and cohesion in the next generation of professionals,
who will be responsible for shaping the future course of benzodiazepine prescribing in primary
care.
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Table 1
Final Themes Identified by Raters Through Thematic Analysis
_____________________________________________________________________________
Main Theme
Sub-Theme
Codes
Number of Extracts
______________________________________________________________________________
Variability in
Resources/Supports
Medical School
Coursework, Hands-off,
8
Optional/Required,
Theory/Practice
Supervision/
Consultation

Clinical/Treatment
Approaches, Autonomy,
Understanding,
Responsibility/Role,
Attending-Resident
Relationship

14

Institutional/Systemic Ethics, Financial, Time,
Protocols
Organizational,
Treatment Protocols,
Medical Field

9

Ambivalence

Clinical
Feeling/Thinking,
Difficult/Conflict,
Lacking Solution, Patient
Outcomes/DecisionMaking

12

Therapeutic
Relationship

Therapeutic
Relationship/Attachment,
Trust/Manipulation,
Conversation, Patient
Motivation/Needs,
Negotiation/Bargaining,
Reinforcement

21

Patient–Provider
Interactions

Empathy

Empathy, Understanding,
13
Patient Feelings,
Treatment Barriers
______________________________________________________________________________
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Table 2
Sample Data Extracts for Each Sub-Theme
______________________________________________________________________________
Main Theme
Sub-Theme
Sample Data Extract
______________________________________________________________________________
Variability in
Resources/Supports
Medical School
But not every single medical student in my
program took it. I think I was the only one
there, so it’s not like the medical curriculum
put me there.

Supervision/
Consultation

I think it’s very subjective. Because every time
we’re supervised, we’re not supervised by the
same attendee. So their approaches are quite
different.

Institutional/Systemic I feel like there are other alternatives that exist,
Protocols
which are better for patients, but because of the
financial burden around them, hospitals, and I
guess the healthcare system itself, discourage
them.
Patient–Provider
Interactions
Ambivalence

Something that is also very challenging about
benzodiazepines, is that, not only are they
addictive, but if you stop taking them acutely,
you can actually die.

Therapeutic
Relationship

You kind of end up in this constant negotiation
with the patient.

______________________________________________________________________________
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Figure 1: Final thematic map and hypothesized relationship between themes.
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conflict of interest in the proposed research study, (e.g., if you are or have been employed at the
research site, have received compensation from a participating organization, have a personal or
professional relationship with any participants).
I was a psychology practicum student at one of the X medical residency sites (X Family Practice)
from August 2017 to August 2018 and had a professional relationship with some of the medical
residents and training directors at this specific site. I received compensation for my training
experience at this site through a federal Graduate Psychology Education (GPE) grant (though I
was not compensated by X directly).
14b. Describe how you will mitigate the bias caused by any conflicts of interest in your study
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and how you will protect the participants against real or potential bias (e.g., you will not recruit
anyone who works directly for you or in your direct team, results will be reported in the
aggregate so that participants will remain anonymous, any compensation received is independent
of the study and its results).
There are multiple training sites within the X medical system, and the three-year nature of this
residency program ensures that the residents with whom I directly worked will have already
completed their training at the time of this research. I will also have another psychology doctoral
peer help review qualitative data in order to minimize possible bias related to my personal
experiences in this setting.
15. Describe the process you will follow to attain informed consent.
Participants will be emailed a copy of the informed consent form for their reference in the initial
recruitment email. At the beginning of each scheduled focus group interview, the researcher will
remind participants that the discussion will be video recorded (though participants can choose to
have their camera turned off if they so desire) and will encourage anyone who is uncomfortable
with this to leave the call if needed (no questions asked). The researcher will then begin
recording. The researcher will proceed to go over the informed consent form in detail, providing
ample space for questions. Those who do not consent will be allowed to leave the call, and oral
consent from each remaining participant will then be obtained.
16. Describe the proposed procedures, (e.g., interview surveys, questionnaires, experiments, etc).
in the project. Any proposed experimental activities that are included in evaluation, research,
development, demonstration, instruction, study, treatments, debriefing, questionnaires, and
similar projects must be described. USE SIMPLE LANGUAGE, AVOID JARGON, AND
IDENTIFY ACRONYMS. Please do not insert a copy of your methodology section from your
proposal. State briefly and concisely the procedures for the project. (500 words)
Focus group participants will be asked about their experiences related to prescribing
benzodiazepines, potential dilemmas that have emerged, and training, supervision, and
consultation experiences and needs through a semi-structured qualitative interview developed by
the researcher (see appended document). Discussion between participants will be encouraged,
and the researcher will moderate/redirect the group back to main interview questions and probes
as needed. Focus group interviews will last approximately forty-five minutes total (including
time allocated to informed consent at the beginning) and will be conducted via Zoom video
conferencing technology. Discussions will be recorded for later transcription. Interview data will
be analyzed in accordance with Braun and Clarke’s (2006) six-step thematic analysis approach.
Interviews will be coded by two independent raters (one of whom will be the primary researcher
and interviewer, the other of whom will be a peer from the psychology doctoral program).
17. Participants in research may be exposed to the possibility of harm - physiological,
psychological, and/or social - please provide the following information: (Up to 500 words)
a. Identify and describe potential risks of harm to participants (including physical, emotional,
financial, or social harm).
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Participants might find the process of discussing potentially challenging patient encounters
around controlled substances (and their own responses as providers) with a researcher from
another discipline to be a somewhat vulnerable experience. There is a potential risk of emotional
distress in the form of frustration, embarrassment, shame, regret, or fear of negative judgment.
Prior experiences, individual personality and coping styles, and previous opportunities to process
these experiences with trusted supports or supervisors may influence the extent to which
participants feel equipped to share openly and/or effectively cope with content discussed during
group interviews, and the researcher should be sensitive to these variables.
b. Identify and describe the anticipated benefits of this research (including direct benefits to
participants and to society-at-large or others)
This research seeks to identify ways in which medical training models might better support
emerging primary care providers in addressing a difficult clinical issue. This has implications for
both provider and patient wellbeing. Participants might also gain some direct benefit from being
allowed to process and communicate their challenges and concerns around prescribing
benzodiazepines through a supportive interaction with peers and the researcher.
c. Explain why you believe the risks are so outweighed by the benefits described above as to
warrant asking participants to accept these risks. Include a discussion of why the research
method you propose is superior to alternative methods that may entail less risk.
Decision-making around prescribing benzodiazepines is associated with a number of risks,
complications, and legal concerns. Research suggests that patient encounters around controlled
substances are particularly stressful and challenging for primary care providers. However, little
research has been done to delineate how to best support them in navigating the potential ethical
dilemmas that may ensue. Though participants in this study may be required to display some
vulnerability in sharing about their difficulties, the data collected will be critical to informing
future interventions that may improve provider training and support.
d. Explain fully how the rights and welfare of participants at risk will be protected (e.g.,
screening out particularly vulnerable participants, follow-up contact with participants, list of
referrals, etc.) and what provisions will be made for the case of an adverse incident occurring
during the study.
Participants will be made aware during informed consent that they can decline to respond to any
questions (without additional probing by the researcher) if doing so would cause undue
emotional distress. They will be free to contribute as much or as little as they desire to the group
discussion. Participants will be free to withdraw from the study at any point without negative
repercussions (in which case their individual contributions to the discussion will not be included
in data analysis or reported). Data will be reported in aggregate form so as to protect the
identities of individual participants. At the end of the group interview, participants will be invited
to contact the researcher privately to schedule additional individual debriefing time if needed to
process difficult emotions that may have come up during the discussion.
18. Explain how participants' privacy is addressed by your proposed research. Specify any steps
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taken to safeguard the anonymity of participants and/or confidentiality of their responses.
Indicate what personal identifying information will be kept, and procedures for storage and
ultimate disposal of personal information. Describe how you will de-identify the data or attach
the signed confidentiality agreement on the attachments tab (scan, if necessary). (Up to 500
words)
The researcher will conduct virtual focus group interviews in private meeting spaces using
appropriate accommodations, such as headsets and/or white noise machines if needed to ensure
individual participant and group confidentiality. Participants will be encouraged to find similarly
private meeting spaces at their discretion. Participants will be reminded not to share patient
protected health information (PHI) as specified under the Health Insurance Portability and
Accountability Act (HIPAA). They will be encouraged to respect the privacy of other group
members with regards to content shared during the discussion. Interview recordings will be
transferred to a secure cloud-based storage program (DropBox) on a password protected
computer directly following interviews. Verbal dialogue from recordings will be transcribed for
thematic analysis; during this process any major identifying information (and video footage) will
be removed from interviews. Digital recordings and transcriptions will be kept until final
research analysis is complete and will be destroyed after this period. For additional
confidentiality and security purposes, each participant will be assigned a number code. Files and
data spreadsheets will be labeled using this code only. Any documents linking participant name
and number codes will be password protected and stored on an additional password protected
computer.
19. Will audio-visual devices be used for recording participants? Will electrical, mechanical
(e.g., biofeedback, electroencephalogram, etc.) devices be used?
Yes
If YES, describe the devices and how they will be used:
Zoom interviews will be recorded using the built-in video recording feature. However, individual
participants may choose to be recorded on an audio-only basis by turning off their video feature
during the interview. Though residents will be familiar with Zoom prior to the meeting,
technological assistance will be provided as needed.
20. Type of Review:
Please provide your reasons/justification for the level of review you are requesting.
Expedited. The proposed research involves the use of interview procedures. Participants are not
considered a vulnerable population. The research presents no more than minimal risk (some
possible emotional discomfort) to participants. Additional risk-mitigation and support protocols
will be enacted to minimize emotional distress. Protocols will be followed to ensure that
participants cannot be individually identified from interview data and authorities within the
organization will not be told which individuals choose to participate in the study (to ensure no
risks related to professional reputation, employment, etc.). My proposal has been approved by
my committee. The organization from which the research will be collected is in full support of
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the study and is eager to use findings to improve future training and support programs.
This research has been approved for submission by my advisor and by others as required by my
program (e.g., my departmental IRB representative, thesis or dissertation committee or course
instructor as applicable).
Yes
21. Informed consent and/or assent statements, if any are used, are to be included with this
application. If information other than that provided on the informed consent form is provided
(e.g. a cover letter), attach a copy of such information. If a consent form is not used, or if consent
is to be presented orally, state your reason for this modification below. *Oral consent is not
allowed when participants are under age 18.
See appended recruitment email and appended informed consent form
22. If questionnaires, tests, or related research instruments are to be used, then you must attach a
copy of the instrument at the bottom of this form (unless the instrument is copyrighted material),
or submit a detailed description (with examples of items) of the research instruments,
questionnaires, or tests that are to be used in the project. Copies will be retained in the permanent
IRB files. If you intend to use a copyrighted instrument, please consult with your research
advisor and your IRB chair. Please clearly name and identify all attached documents when you
add them on the attachments tab.
See appended document for interview protocol/questions
I have agreed to conduct this project in accordance with Antioch University's policies and
requirements involving research as outlined in the IRB Manual and supplemental materials.
I certify that I have attached documentation confirming completion of the CITI Modules.
Yes
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Appendix B: Redacted Letter of Support from Medical Training Site
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Appendix C: Informed Consent Form
Study Title: Physician Training and Support in Managing Dilemmas around Benzodiazepine
Prescribing
Investigator: Elizabeth Corley, M.S., Clinical Psychology Doctoral Candidate
Dissertation Chair: X
_____________________________________________________________________________
1. The purpose of this study is to investigate the training, supervision, and consultation
experiences and needs of medical residents with regards to managing difficult patient
encounters around benzodiazepine prescriptions.
2. Should I choose to participate, I will be asked to engage in an audio recorded thirtyminute virtual focus group interview. Interview questions will inquire about clinical
experiences related to benzodiazepine prescription and related supervision, consultation,
and training. I may decline to answer any questions if doing so would cause undue
distress.
3. Participation in this study is entirely voluntary. I may refuse to participate or withdraw at
any time without creating any harmful consequences to myself. My data will not be used
if I choose to withdraw. I realize that, due to the focus group nature of the study, it may
be difficult to guarantee that all of my individual contributions to the group are removed
should I choose to withdraw, but the investigator will make all reasonable efforts to do
so.
4. Possible risks of this study include: emotional discomfort when discussing difficult
patient encounters. I may schedule additional debriefing time with the investigator (which
will not be recorded or included in research data) if needed.
5. I may find the opportunity to communicate and reflect on my experiences to be of some
direct benefit to my clinical practice. Information I share in the group may directly
benefit other group members, or indirectly benefit other providers and patients by helping
to improve medical training models.
6. Personal identifiers will be removed from the final data set, and my de-identified
information will not be used or distributed for future research. Results will be reported in
aggregate form, and direct quotes will not be shared unless they are illustrative of general
themes observed within the larger group and present no risk of individual identification.
7. The investigator may include the data and results of the study in future scholarly
publications and presentations. The confidentiality agreement, as articulated above, will
be effective in all cases of data sharing.
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If you have any questions about the study, you may contact the principal investigator, Elizabeth
Corley, M.S. at: X or X or the research supervisor, X, at: X or X.
If you have any questions about your rights as a research participant, you may contact Antioch
University New England’s IRB Chair, X at: X or X or Provost, X at: X or X.

I have reviewed this form in its entirety with the investigator, understand the information
discussed, and consent to participate in this study.
___________________________
SIGNATURE

___________________
DATE
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Appendix D: Recruitment Email
Dear Resident,
I am a clinical psychology doctoral candidate at Antioch University New England. I am seeking
participants for my dissertation research. My IRB-approved study will examine the training,
supervision, and consultation experiences and needs of medical residents with regards to
managing difficult patient encounters around benzodiazepine prescriptions.
To participate in this research:
1. You must have at least three months of experience providing direct contact to patients
(telehealth counts).
2. You must have experienced at least one patient encounter related to benzodiazepine
prescription (e.g., being asked to adjust, begin, or discontinue medication).
Participation involves:
1. A one-time commitment of thirty minutes (which will begin during regularly scheduled
didactics time) for a Zoom focus group interview.
2. A willingness to have the interview audio recorded.
3. Group discussion of clinical experiences related to benzodiazepine prescription and
related supervision, consultation, and training.
The focus group will be held during the final portion of didactics on X between X and X. To
participate, all you need to do is stay on the Zoom call as usual (though you are welcome to leave
if you are not qualified or do not wish to participate). Training directors will end normal
didactics 15 minutes early and will leave the call so as not to see who chooses to participate. All
individual identifying information will be kept confidential.
Participants will have an opportunity to provide valuable data that may inform future training
models. More information can be viewed in the informed consent form attached below.
If you plan on attending, please send me a quick email so we know how many people to expect.
Thank you for your consideration!
Elizabeth Corley, M.S.

